102 results
8-K
EVOK
Evoke Pharma Inc
28 May 24
Departure of Directors or Certain Officers
4:17pm
is entitled to the following payments and benefits: (1) fully earned but unpaid base salary through the date of termination at the rate then in effect … occurs, prorated for the period of his service during such year; and (4) continued healthcare benefits for a period of nine months. In the event Mr
8-K
EX-99.1
EVOK
Evoke Pharma Inc
14 May 24
Evoke Pharma Reports First Quarter 2024 Financial Results
4:15pm
of nasal metoclopramide in women with gastroparesis, highlighting its benefits and practical application,” Mr. D’Onofrio concluded.
Fourth Quarter
424B3
egr2mgv d9un02odv8
14 Mar 24
Prospectus supplement
6:44pm
8-K
EX-99.1
80snoioaig dt36xp6lr
14 Mar 24
Evoke Pharma Reports Fourth Quarter and Full Year 2023 Financial Results
4:00pm
8-K
EX-4.1
79rwdtrncd9c1
14 Feb 24
Unregistered Sales of Equity Securities
9:00am
8-K
EX-1.1
mu5rfk0rw 3y33qjyk
9 Feb 24
Evoke Pharma Announces Pricing of Underwritten Public Offering of up to $30 Million
5:15pm
424B4
d5cxqspd
9 Feb 24
Prospectus supplement with pricing info
5:14pm